非小细胞肺癌免疫治疗研究进展
Advances in Immune Therapy for Non Small Cell Lung Cancer

作者: 江鑫辉 :上海中医药大学附属曙光医院宝山分院,上海; 寿伟臻 :上海中医药大学附属龙华医院,上海;

关键词: 非小细胞肺癌免疫治疗进展Non Small Cell Lung Cancer Immunotherapy Progress

摘要: 目前肺癌已成为所有癌症中发病人数最多的疾病,其死亡率逐年呈上升趋势。近年来,虽然以化疗为主的综合疗法使非小细胞肺癌患者的生存率有所提高,但是患者总体5年生存率较低,并且由于放化疗的附加损害,患者的生活质量和实际生存率并未显著改变。近几年随着肿瘤免疫学及分子生物学研究的进一步深入与完善,肺癌的免疫治疗得到广泛关注,并为非小细胞肺癌患者的治疗提供了新的方向。本文对当前非小细胞肺癌免疫治疗的研究概况进行综述。

Abstract: At present, lung cancer has become the leading cause of death in various types of cancer, the inci-dence and mortality rate is rising. In recent years, although non small cell lung cancer patients survival rate prolongs the combination therapy with chemotherapy, patients and the overall 5- year survival rate is very low, and due to the additional damage of radiotherapy and chemotherapy, the patient’s quality of life and the actual survival rate did not significantly change. In recent years, with the further development and improvement of tumor immunology and molecular biology, immune therapy of lung cancer has been widely concerned, and provides a new direction for the treatment of non-small cell lung cancer patients. This review summarizes the current research progress in the treatment of non small cell lung cancer.

文章引用: 江鑫辉 , 寿伟臻 (2016) 非小细胞肺癌免疫治疗研究进展。 医学诊断, 6, 15-20. doi: 10.12677/MD.2016.61004

参考文献

[1] 姚晓军, 刘伦旭. 肺癌的流行病学及治疗现状[J]. 现代肿瘤医学, 2015, 22(8): 1982-1986.

[2] 蒋涛, 周彩存. T细胞相关免疫疗法在非小细胞肺癌治疗中的研究进展[J]. 肿瘤, 2015(8): 930-935.

[3] Ettinger, D.S., Akerley, W., Borghaei, H., et al. (2012) Non-Small-Cell Lung Cancer. Journal of the National Comprehensive Cancer Network, 10, 1236-1271.

[4] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. (2011) Genotypic and Hisological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Science Translational Medicine, 3, 75ra26.

[5] The Cancer Genome Atlas Research Network (2014) Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature, 511, 543-550.
http://dx.doi.org/10.1038/nature13385

[6] Reck, M. (2012) What Future Opportunities May Im-muno-Oncology Provide for Improving the Treatment of Patients with Lung Cancer? Annals of Oncology, 23, viii28-viii34.
http://dx.doi.org/10.1093/annonc/mds260

[7] Brahmer, J.R. (2013) Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 31, 1021-1028.
http://dx.doi.org/10.1200/JCO.2012.45.8703

[8] Jadus, M.R., Natividad, J., Mai, A., et al. (2012) Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention. Clinical and Developmental Immunology, 2012, 160724.

[9] Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570.
http://dx.doi.org/10.1126/science.1203486

[10] 程森森, 马原, 宋宝. 非小细胞肺癌免疫治疗最新进展与挑战[J]. 中国肿瘤临床, 2015, 42(20): 1031-1036.

[11] 刘文苏, 韩欢. 免疫系统与肿瘤机制研究[J]. 科技风, 2015(14): 113.

[12] 黄丽斌, 石磊, 杨卫兵. 非小细胞肺癌抗肿瘤免疫应答与免疫逃逸相关研究[J]. 贵州医药, 2014(2): 172-175.

[13] Tomasini, P., Khobta, N., Greillier, L., et al. (2012) Ipilimumab: Its Potential in Nonsmall Cell Lung Cancer. Therapeutic Advances in Medical Oncology, 4, 43-50.
http://dx.doi.org/10.1177/1758834011431718

[14] 徐燕. 非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2014, 1(17): 34-41.

[15] 张新, 许燕华. 非小细胞肺癌免疫治疗研究进展[J]. 上海医药, 2015(15): 19-22.

[16] 孟祥姣, 邢力刚, 于金明. 非小细胞肺癌免疫检查点阻断剂治疗进展[J]. 中国肿瘤临床, 2015, 42(18): 887-890.

[17] 王延朋. 细胞免疫治疗同步全身化疗在晚期肺癌治疗效果研究[J]. 中国实用医药, 2015, 10(3): 1003-1005.

[18] 田林晓, 李小光. 非小细胞肺癌的免疫治疗现状[J]. 中外医疗, 2015(31): 196-198.

[19] 张力. 非小细胞肺癌的免疫治疗新进展[J]. 医学与哲学(B), 2015(2): 13-17.

[20] 林城, 陈雄, 刘静南, 等. PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展[J]. 中国肺癌杂志, 2014(10): 734-740.

[21] 任军, 黄红艳. 靶向免疫检查点的肿瘤免疫治疗现状与趋势[J]. 中国肿瘤临床, 2014(7): 415-419.

[22] 韩策, 尤向辉, 聂娜. 肿瘤免疫治疗研究进展[J]. 陕西医学杂志, 2015, 4(44): 502-503.

[23] 高亭, 蒋引娣, 李敏, 等. 非小细胞肺癌的免疫学治疗进展[J]. 临床肺科杂志, 2015(10): 1893-1896.

[24] 廖云梅, 阮志华. 肿瘤微环境在肿瘤免疫治疗中的研究进展[J]. 免疫学杂志, 2014(12): 1104-1107.

[25] 陈影, 杜向慧. 非小细胞肺癌免疫治疗临床新进展[J]. 医学研究杂志, 2015(5): 12-15.

[26] 蒋涛, 周彩存. T细胞相关免疫疗法在非小细胞肺癌治疗中的研究进展[J]. 肿瘤, 2015(8): 930-935.

[27] Jin, C.G., Chen, X.Q., Li, J., et al. (2013) Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy. Asian Pacific Journal of Cancer Prevention, 14, 3587-3592.
http://dx.doi.org/10.7314/APJCP.2013.14.6.3587

[28] Cui, Y., Yang, X., Zhu, W., et al. (2013) Immune Response, Clinical Outcome and Safety of Endritic Cell Vaccine in Combination with Cytokine-Induced Killer Cell Therapy in Cancer Patients. Oncology Letters, 6, 537-541.

[29] 孟凡珍, 江涛. 非小细胞肺癌基因治疗的研究进展[J]. 癌症进展, 2010(6): 568-571.

[30] 任维维. 生物免疫治疗非小细胞肺癌的系统评价和Meta分析[D]. 兰州: 兰州大学, 2014.

[31] 张波. 晚期非小细胞肺癌的靶向治疗[D]. 丁香园, 2015.

[32] Wolchok, J.D., Hoos, A., O’Day, S., et al. (2009) Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 15, 7412-7420.
http://dx.doi.org/10.1158/1078-0432.CCR-09-1624

[33] 张斌, 陈虎. 肿瘤免疫细胞治疗的质量管理和疗效评价[J]. 中国肿瘤生物治疗杂志, 2015, 22(1): 8-15.

[34] 任秀宝, 于津浦. 肿瘤免疫治疗疗效评价的新标准[J]. 中国肿瘤生物治疗杂志, 2011(4): 351-354.

分享
Top